## STATE OF NEW YORK

6606

2019-2020 Regular Sessions

## IN ASSEMBLY

March 14, 2019

Introduced by M. of A. CRESPO -- read once and referred to the Committee on Consumer Affairs and Protection

AN ACT to amend the general business law, in relation to the price gouging of pharmaceuticals

## The People of the State of New York, represented in Senate and Assembly, do enact as follows:

| 1   | Section 1. The general business law is amended by adding a new section   |
|-----|--------------------------------------------------------------------------|
| 2   | 396-rrr to read as follows:                                              |
| 3   | § 396-rrr. Price gouging; pharmaceuticals. 1. For the purposes of        |
| 4   | this section, "pharmaceuticals" shall mean any compound manufactured for |
| 5   | <u>sale as a medicinal drug.</u>                                         |
| б   | 2. No manufacturer or wholesaler of pharmaceuticals shall sell or        |
| 7   | offer to sell pharmaceuticals for an amount which represents an uncon-   |
| 8   | scionably excessive price. Whether a price is unconscionably excessive   |
| 9   | <u>is a question of law for the court.</u>                               |
| 10  | 3. The court's determination that a violation of this section has        |
| 11  | occurred shall be based on any of the following factors:                 |
| 12  | (a) that the amount of the excess in price is unconscionably extreme;    |
| 13  | (b) that there was an exercise of unfair leverage or unconscionable      |
| 14  | means; or                                                                |
| 15  | (c) a combination of both factors.                                       |
| 16  | 4. In any court proceeding commenced pursuant to this section, proof     |
| 17  | that a violation of this section has occurred shall include evidence     |
| 18  | <u>that:</u>                                                             |
| 19  | (a) the amount charged represents a gross disparity between the market   |
| 20  | price of the pharmaceutical that led to the action under this section    |
| 21  | and the price of the same pharmaceutical over the six months prior to    |
| 22  | the price change that led to the action under this section; or           |
| 23  | (b) the amount charged grossly exceeded the price at which the pharma-   |
| 2.4 | ceuticals were readily obtainable by other purchasers.                   |

EXPLANATION--Matter in **italics** (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD05326-01-9

| 1  | 5. A defendant may rebut a prima facie case with evidence that addi-     |
|----|--------------------------------------------------------------------------|
| 2  | tional costs not within the control of the defendant were imposed on the |
| 3  | defendant.                                                               |
| 4  | 6. Where a violation of this section is alleged to have occurred, the    |
| 5  | attorney general may apply in the name of the people of the state of New |
| б  | York to the supreme court within the judicial district in which such     |
| 7  | violation is alleged to have occurred, on notice of five days, for an    |
| 8  | order enjoining or restraining commission or continuance of the alleged  |
| 9  | unlawful acts. In any such proceeding where a violation is found to have |
| 10 | occurred, the court shall impose a civil penalty in an amount not to     |
| 11 | exceed one million dollars and, where appropriate, order restitution to  |
| 12 | aggrieved consumers.                                                     |
| 13 | § 2. This act shall take effect immediately.                             |